Edward D. Esplin: Clinician Responses to Germline Genetic Testing in Prostate Cancer Management

Edward D. Esplin, Clinical Geneticist at Invitae, shared on X:

“Up to 17% of prostate cancer patients have PGVs with germline testing

36% of universally tested PC patients had positive health outcomes 2/2 genetic testing results

Shore et al.

‘This study supports universal germline genetic testing for patients with prostate cancer, and it demonstrates the clinical utility of germline genetic testing results—both positive and negative—for…the care of patients and their families.’”

Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer

Authors: Neal Shore, Christopher Pieczonka, Sean Heron, Mukaram Gazi, David Cahn, Laurence H. Belkoff, Aaron Berger, Brian Mazzarella, Joseph Veys, Charles Idom, David Morris, Gautam Jayram, Alexander Engelman, Paul Dato, Richard Bevan-Thomas, David R. Wise, Mary Kay Hardwick, Susan Rojahn, Paige Layman, Brandie Heald, Rachel E. Ellsworth, Kathryn E. Hatchell, Robert L. Nussbaum, Sarah M. Nielsen, Edward D. Esplin

Source: Edward D. Esplin/X